Sunshine Biopharma (SBFMW) Equity Average (2016 - 2025)
Historic Equity Average for Sunshine Biopharma (SBFMW) over the last 13 years, with Q3 2025 value amounting to $24.9 million.
- Sunshine Biopharma's Equity Average rose 279.21% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 279.21%. This contributed to the annual value of $22.4 million for FY2024, which is 437.3% up from last year.
- Sunshine Biopharma's Equity Average amounted to $24.9 million in Q3 2025, which was up 279.21% from $24.2 million recorded in Q2 2025.
- Over the past 5 years, Sunshine Biopharma's Equity Average peaked at $41.1 million during Q3 2022, and registered a low of -$1.0 million during Q3 2021.
- For the 5-year period, Sunshine Biopharma's Equity Average averaged around $18.8 million, with its median value being $23.0 million (2024).
- As far as peak fluctuations go, Sunshine Biopharma's Equity Average skyrocketed by 654431.45% in 2022, and later tumbled by 4521.33% in 2023.
- Sunshine Biopharma's Equity Average (Quarter) stood at -$481135.0 in 2021, then skyrocketed by 6544.31% to $31.0 million in 2022, then plummeted by 30.38% to $21.6 million in 2023, then rose by 12.44% to $24.3 million in 2024, then rose by 2.77% to $24.9 million in 2025.
- Its Equity Average stands at $24.9 million for Q3 2025, versus $24.2 million for Q2 2025 and $23.1 million for Q1 2025.